News Amgen/UCB's osteoporosis drug hit by cardio risk Competitor to Amgen's Epogen also moves closer to market
News Data keeps Lilly in race for new migraine treatment Company still in race to develop CGRP inhibitor for migraine.
News NICE backs Amgen's Blincyto in rare leukaemia Drug will also be available to children via Cancer Drugs Fund.
News UK court overturns AbbVie Humira patents Decision paves way for cheaper competitor in autumn 2018.
News US drug revenues far exceed R&D spend - report Analysis questions industry's rationale for high US prices.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
